The FTC Should Think Hard Before Suing PBMs

In the wake of an interim staff report released Tuesday on the relationship between pharmacy benefit managers (PBMs) and American pharmaceuticals, it looks like the FTC is planning to sue three of the largest PBMs for the way they’ve negotiated drug prices. 

While protecting consumers from unfair or deceptive trade practices certainly falls under the FTC’s purview, their lawsuit will be based on a flawed report. The FTC should do its research before rushing ahead to sue on shaky grounds.